Silexion Therapeutics completes initial study of SIL-204 in pancreatic cancer models, assessing tumor growth and metastasis. Results expected in March 2025. Silexion Therapeutics Corp. announced the ...

Pancreatic ductal adenocarcinoma (PDAC), is highly aggressive and lethal. It is the most prevalent type of pancreatic cancer, making up 90% of cases; it also has a high rate of metastasis, with an ...

Microscopic image with a star-shaped lumen on the left and a spherical lumen on the right. The apical marker Ezrin shown in green marks the lumen surface. Tissue engineering the pancreas: Working with ...

A brief illustration of the main cellular processes and biological pathways that contribute to the development of Pancreatic cancer, with emphasis on the genetic mutations and cellular alterations.

Grand Cayman, Cayman Islands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA ...

SIL-204's ability to reduce primary tumor growth when administered systemically in orthotopic pancreatic cancer models, where human tumor cells are implanted directly into the pancreas SIL-204's ...

Researchers at MIT’s CSAIL division, which focuses on computer engineering and AI development, built two machine learning algorithms that can detect pancreatic cancer at a higher threshold than ...

Pancreas development in pigs resembles humans much more closely than does the established mouse model. An international team headed by Helmholtz Munich and the German Center for Diabetes Research (DZD ...